Post-Approval Trial of the Talent™ Abdominal Stent Graft to Treat Aortic Aneurysms

The purpose of this study is to examine, through the endpoints established in this protocol, the long-term safety and effectiveness of the Talent Abdominal Stent Graft System, in a post-approval environment.

The Talent Abdominal Stent Graft System is a next-generation modular system for endovascular repair of Abdominal Aortic Aneurysm (AAA). The system was designed with the following enhancements: a suprarenal wire frame to provide migration resistance, and improved flexibility designed to treat difficult anatomies.

Medtronic Vascular submitted a Pre-Market Application (PMA) to the Food and Drug Administration (FDA) on October 17, 2007, and received market approval for the Talent Abdominal Stent Graft System on April 15th, 2008. As a condition of approval, the FDA has requested a post-approval study. Medtronic has therefore designed a post-approval study, in collaboration with FDA, to document the performance of the Talent Abdominal Stent Graft System under market conditions.

Eligibility Criteria:
Inclusion Criteria:

* Subject must have an abdominal aortic aneurysm, with or without iliac involvement.
* Iliac/femoral access vessel morphology that is compatible with vascular access techniques, devices, and/or accessories;
* A proximal aortic neck length of ≥ 10mm;
* Proximal aortic neck angulation ≤ 60°;
* Distal iliac artery fixation length of ≥ 15mm;
* An aortic neck diameter of 18-32mm and iliac artery diameters of 8-22mm; and
* Vessel morphology suitable for endovascular repair.

Exclusion Criteria:

* Are less than 18 years of age
* Are pregnant or lactating
* Have a dominant patent inferior mesenteric artery and an occluded or stenotic celiac and/or superior mesenteric artery
* Have aneurysmal involvement or occlusion (surgically performed or naturally occurring) of the bilateral internal iliac arteries
* Have vessels and/or aneurysm dimensions that cannot accommodate the Talent Abdominal Stent Graft as per the indications in Section 3.
* Have no distal vascular bed (one vessel lower extremity run-off required)
* Have contraindications for use of contrast medium or anticoagulation drugs
* Have an uncorrectable coagulopathy
* Have an SVS/AAVS score greater than 2
* Have a mycotic aneurysm
* Have circumferential mural thrombus in the proximal aortic neck
* Have had a recent (within 3 months) myocardial infarction (MI), cerebral vascular accident (CVA), or major surgical intervention
* Have traumatic aortic injury
* Have leaking, pending rupture or ruptured aneurysms
* Have pseudoaneurysms resulting from previous graft placement
* Require a revision to previously placed endovascular stent grafts.
* Have genetic connective tissue disease (e.g., Marfan's or Ehlers-Danlos' Syndromes)
* Have concomitant thoracic aortic or thoracoabdominal aneurysms
* Are patients with active systemic infections
* Are patients who have a condition that threatens to infect the graft.
* Are patients with sensitivities or allergies to the device materials.
* Have access vessels (as determined by treating physician) that preclude safe insertion of the delivery system. NOTE: Iliac conduits may be used to ensure the safe insertion of the delivery system.